Clinical Trial Update: Risk-adapted Therapy for Primary Systemic (AL) Amyloidosis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating risk-adapted therapy for primary systemic AL amyloidosis; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Al Amyloidosis

Snippet

Sponsor: FDA Office of Orphan Products Development | Conditions: Amyloidosis | Phase 2 | Status: COMPLETED